CVS Health's Comeback Is Just Getting Started -- and Its Valuation Still Looks Shockingly Cheap

CVS Health reported Q1 revenue of $100.4 billion, up about 6% year over year, with adjusted EPS rising 14% to $2.57 and results ahead of analyst estimates. The company also raised its FY2026 EPS guidance, while its medical benefit ratio fell to 84.6% from 87.3%, supporting margin recovery. Longer term, CVS highlighted a 2.6% forward dividend yield, 56.5% decade-long dividend growth, and a relatively cheap 13.8x forward P/E versus the healthcare sector's 17.4x average.

Analysis

CVS looks less like a simple rerating story and more like a turnaround in mix: management is consciously sacrificing top-line breadth to protect underwriting quality and operating leverage. That matters because in managed care, the market usually rewards lower volatility in margins more than headline growth; if the earnings inflection is real, the stock can keep compounding even with slower revenue. The key second-order effect is that better claims discipline should also improve CVS’s capital flexibility, which can support buybacks or dividend growth without needing heroic multiple expansion.

The main beneficiary is CVS itself, but the competitive spillover is important: rivals with weaker medical cost control or heavier MA exposure may be forced into more conservative pricing and utilization management, which can suppress industry growth but stabilize returns. The digitization of prior auth is also an underappreciated margin lever because it reduces administrative friction and should lower SG&A per member over several quarters, not just one quarter. If that workflow improvement scales, it can create a durable operating gap versus peers with more fragmented care coordination.

The market is likely underpricing two risks: first, the apparent improvement in MBR can reverse quickly if utilization normalizes upward into the next renewal cycle; second, shrinking MA exposure could mechanically reduce reported revenue and obscure continued earnings progress, creating intermittent disappointment windows. This is a stock where the path matters more than the destination: good months can be followed by bad guideposts if membership mix shifts faster than investors expect. For that reason, the setup favors buying on pullbacks rather than chasing strength, especially ahead of benefit-ratio or guidance updates.

The contrarian view is that CVS may still deserve a discount multiple because the earnings recovery is not purely self-help; a lot depends on sustaining pricing discipline in a structurally competitive insurance market. That said, the current valuation already prices in a lot of skepticism, so even modest execution can produce outsized upside over the next 6-12 months. The asymmetric setup is that downside likely requires a fresh utilization surprise, while upside can be unlocked by several incremental beats rather than one transformational event.

Key Decisions for Investors

• Long CVS on a 6-12 month horizon; add on weakness after any guide-related selloff. Risk/reward is attractive if earnings momentum persists and the market re-rates the name even modestly toward low-teens sector multiples.
• Pair trade: long CVS / short a higher-MBR or more operationally fragile managed-care peer basket for 3-6 months. The trade expresses relative underwriting discipline and should work if utilization remains contained.
• Sell cash-secured puts on CVS 1-2 quarters out at strikes ~8-12% below spot to harvest elevated implied volatility around earnings/guidance risk. Best used only if willing to own the name on a dip.
• If holding a core CVS position, finance part of it with covered calls 1-2 months out into strength. The thesis is grind-up, not a straight line, so call overwriting monetizes volatility while preserving downside participation.
• Watch for any renewed MA utilization spike or guidance reset; if that appears, cut exposure quickly because the stock can de-rate faster than fundamentals can be revised.